BioArctic AB (STU:B9A) OCF Margin %: -37.94% (As of Mar. 2026)


STU:B9A BioArctic AB STU:B9A
75 GF Score
Price €27.88
GF Value €44.04
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is BioArctic AB OCF Margin %?

BioArctic AB STU:B9A +1.23% 75 OCF Margin % is -37.94% as of Mar. 2026. GuruFocus rates STU:B9A with a GF Score™ of 75/100 and a GF Value™ of €44.04 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 960 Biotechnology companies, BioArctic AB ranks better than 98.54% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. BioArctic AB's Cash Flow from Operations for the three months ended in Mar. 2026 was €-15.4 Mil. BioArctic AB's Revenue for the three months ended in Mar. 2026 was €40.6 Mil. Therefore, BioArctic AB's OCF Margin % for the quarter that ended in Mar. 2026 was -37.94%.

As of today, BioArctic AB's current OCF Yield % is 4.52%.

The historical rank and industry rank for BioArctic AB's OCF Margin % or its related term are showing as below:

STU:B9A' s OCF Margin % Range Over the Past 10 Years
Min: -606.83   Med: -20.94   Max: 639.25
Current: 108.11

During the past 11 years, the highest OCF Margin % of BioArctic AB was 639.25%. The lowest was -606.83%. And the median was -20.94%.

STU:B9A's OCF Margin % is ranked better than
98.54% of 960 companies
in the Biotechnology industry
Industry Median: -68.59 vs STU:B9A: 108.11

BioArctic AB OCF Margin % Related Terms

BioArctic AB OCF Margin % Historical Data

* Premium members only.

The historical data trend for BioArctic AB's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioArctic AB OCF Margin % Chart

BioArctic AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -606.70 -13.86 50.28 -122.92 71.59

BioArctic AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.91 292.55 -30.89 170.26 -37.94

STU:B9A vs VRTX, REGN, ALNY: OCF Margin % Comparison

For the Biotechnology subindustry, BioArctic AB's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioArctic AB OCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioArctic AB's OCF Margin % distribution charts can be found below:

* The bar in red indicates where BioArctic AB's OCF Margin % falls into.


STU:B9A
75GF Score
BioArctic AB STU:B9A
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioArctic AB OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

BioArctic AB's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=131.504/183.703
=71.59 %

BioArctic AB's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-15.412/40.625
=-37.94 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of -37.94% mean?
BioArctic AB (STU:B9A) has a OCF Margin % of -37.94% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on BioArctic AB and its competitors. According to the industry distribution chart, BioArctic AB ranks #14 out of 960 companies in the Biotechnology industry, placing it in the top 1.5%.
Is BioArctic AB's OCF Margin % too high?
BioArctic AB's current OCF Margin % is -37.94%. Based on the distribution chart, BioArctic AB ranks #14 out of 960 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, BioArctic AB has a GF Score™ of 75/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioArctic AB's OCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BioArctic AB ranks #14 out of 960 companies for OCF Margin %. This places BioArctic AB in the top 2% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on BioArctic AB and its competitors. BioArctic AB's current OCF Margin % is -37.94%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioArctic AB stock overvalued right now?
Based on GuruFocus' analysis, BioArctic AB (STU:B9A) is currently considered Significantly Undervalued. The stock's GF Value™ is €44.04, compared to a current price of €27.88 — trading 36.7% below its estimated fair value. The current OCF Margin % is -37.94%. BioArctic AB's overall GF Score™ is 75/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For BioArctic AB (STU:B9A), the current OCF Margin % is -37.94% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioArctic AB (STU:B9A) Overvalued in 2026?

Based on GuruFocus' analysis, BioArctic AB stock appears to be undervalued. The current stock price of €27.88 is trading 36.7% below its estimated GF Value™ of €44.04. GuruFocus considers BioArctic AB to be Significantly Undervalued.

Key valuation signals for STU:B9A:

  • OCF Margin %: -37.94%
  • GF Value™: €44.04 vs. price of €27.88 (36.7% below fair value)
  • GF Score™: 75/100 with 2 warning signs

No single metric tells the full story. See the STU:B9A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioArctic AB Business Description

Address Warfvinges vag 35, Stockholm, SWE, SE-112 51
BioArctic AB is a research-based biopharmaceutical company focusing on disease-modifying treatments and diagnostics for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, and ALS. Geographically, it derives a majority of its revenue from North America.
75GF Score

Get the complete analysis for STU:B9A

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€27.88
Price
€44.04
GF Value